Literature DB >> 18455119

p53 Activation: a case against Sir.

Christopher L Brooks1, Wei Gu.   

Abstract

The p53 tumor suppressor is a critical transcription factor for controlling cell growth and apoptosis during times of cellular stress. In this issue of Cancer Cell, Lain et al. have used a p53-responsive reporter gene as the readout for screening small-molecule activators of p53 that could potentially reduce tumor growth. Using this approach, tenovin-6 was identified as a potent SIRT1 and SIRT2 inhibitor that indirectly activated p53 at single-digit micromolar concentrations. The identification of a specific sirtuin inhibitor has broad implications in understanding sirtuin-p53 signaling and the development of novel chemotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455119      PMCID: PMC2856338          DOI: 10.1016/j.ccr.2008.04.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  9 in total

Review 1.  Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia.

Authors:  R Scott Lokey
Journal:  Curr Opin Chem Biol       Date:  2003-02       Impact factor: 8.822

Review 2.  A practical view of 'druggability'.

Authors:  Thomas H Keller; Arkadius Pichota; Zheng Yin
Journal:  Curr Opin Chem Biol       Date:  2006-06-30       Impact factor: 8.822

Review 3.  Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

4.  Negative control of p53 by Sir2alpha promotes cell survival under stress.

Authors:  J Luo; A Y Nikolaev; S Imai; D Chen; F Su; A Shiloh; L Guarente; W Gu
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

5.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

Review 6.  Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction.

Authors:  Marcia C Haigis; Leonard P Guarente
Journal:  Genes Dev       Date:  2006-11-01       Impact factor: 11.361

Review 7.  Improving cancer therapy by non-genotoxic activation of p53.

Authors:  S Lain; D Lane
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

8.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

Authors:  Tiago Fleming Outeiro; Eirene Kontopoulos; Stephen M Altmann; Irina Kufareva; Katherine E Strathearn; Allison M Amore; Catherine B Volk; Michele M Maxwell; Jean-Christophe Rochet; Pamela J McLean; Anne B Young; Ruben Abagyan; Mel B Feany; Bradley T Hyman; Aleksey G Kazantsev
Journal:  Science       Date:  2007-06-21       Impact factor: 47.728

Review 9.  Sirtuins in mammals: insights into their biological function.

Authors:  Shaday Michan; David Sinclair
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

  9 in total
  14 in total

1.  The Roles of SIRT1 in Cancer.

Authors:  Zhenghong Lin; Deyu Fang
Journal:  Genes Cancer       Date:  2013-03

2.  p85α mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response.

Authors:  L Song; M Gao; W Dong; M Hu; J Li; X Shi; Y Hao; Y Li; C Huang
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 3.  The p53 pathway as a target in cancer therapeutics: obstacles and promise.

Authors:  Anna Mandinova; Sam W Lee
Journal:  Sci Transl Med       Date:  2011-01-05       Impact factor: 17.956

4.  Sirtuin1 Expression and Correlation with Histopathological Features in Retinoblastoma.

Authors:  Atul Batra; Seema Kashyap; Lata Singh; Sameer Bakhshi
Journal:  Ocul Oncol Pathol       Date:  2015-09-24

Review 5.  Mammalian sirtuins: biological insights and disease relevance.

Authors:  Marcia C Haigis; David A Sinclair
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

6.  The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Authors:  Efrat Shema; Itay Tirosh; Yael Aylon; Jing Huang; Chaoyang Ye; Neta Moskovits; Nina Raver-Shapira; Neri Minsky; Judith Pirngruber; Gabi Tarcic; Pavla Hublarova; Lilach Moyal; Mali Gana-Weisz; Yosef Shiloh; Yossef Yarden; Steven A Johnsen; Borivoj Vojtesek; Shelley L Berger; Moshe Oren
Journal:  Genes Dev       Date:  2008-10-01       Impact factor: 11.361

7.  The sirtuins in the pathogenesis of cancer.

Authors:  Susanne Voelter-Mahlknecht; Ulrich Mahlknecht
Journal:  Clin Epigenetics       Date:  2010-08-20       Impact factor: 6.551

8.  Sirtuin 1 facilitates generation of induced pluripotent stem cells from mouse embryonic fibroblasts through the miR-34a and p53 pathways.

Authors:  Yin Lau Lee; Qian Peng; Sze Wan Fong; Andy C H Chen; Kai Fai Lee; Ernest H Y Ng; Andras Nagy; William S B Yeung
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

9.  Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer.

Authors:  Tiago Baptista; Inês Graça; Elsa J Sousa; Ana I Oliveira; Natália R Costa; Pedro Costa-Pinheiro; Francisco Amado; Rui Henrique; Carmen Jerónimo
Journal:  Oncotarget       Date:  2013-10

10.  Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning.

Authors:  Samuel A Danziger; Roberta Baronio; Lydia Ho; Linda Hall; Kirsty Salmon; G Wesley Hatfield; Peter Kaiser; Richard H Lathrop
Journal:  PLoS Comput Biol       Date:  2008-09-04       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.